European Pharmaceutical Review

FEBRUARY 1, 2023

billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29

Compounding 98

Compounding 98

Pharmacy Times

JANUARY 10, 2023

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

132

132

PharmaVoice

JULY 1, 2024

government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027. As the first 10 drugs undergo price negotiations with the U.S.

130

130

Fierce Pharma

MAY 22, 2024

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year.

109

109

Pharmaceutical Technology

AUGUST 31, 2023

Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.

52

52

Fierce Healthcare

MARCH 21, 2023

by 2027: report pminemyer Tue, 03/21/2023 - 16:11 The payer services market could be worth $118.2B

52

52

BioPharm

OCTOBER 26, 2023

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.

98

98

Drug Store News

JANUARY 30, 2023

The underlying growth rate will be driven by new drug launches and wider use of recently launched brands despite efforts by payers to constrain their budgets, and the impact of lower-cost options.

96

96

STAT

SEPTEMBER 23, 2024

1, and the negotiated prices of those drugs take effect in 2027.  Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs. Medicare will announce that list by Feb.

Specialty Pharmacies 135

Specialty Pharmacies 135

STAT

OCTOBER 26, 2023

About 800,000 nurses plan to leave the workforce by 2027, and more than half of newly graduated nurses are leaving the profession within two years. The Kaiser strike is over, for now, but there is no clear resolution in place, and other strikes are still under way or on the horizon.

Insurance 135

Insurance 135

pharmaphorum

FEBRUARY 6, 2025

BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2,200 job cuts, adding a target of another $2bn by end-2027.

93

93

Drug Store News

APRIL 12, 2023

17, 2027, or earlier based on certain circumstances. Under the agreement, Dr. Reddy’s has the right to market its product beginning Nov.

98

98

Fierce Pharma

AUGUST 16, 2024

Novo Nordisk Pharmatech expects the plant to be complete by 2027. billion Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make raw materials, the company said Friday. The project will result in the creation of 50 new jobs, according to the company.

105

105

STAT

DECEMBER 13, 2024

The nonprofit Howard Hughes Medical Institute (HHMI) will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for a round of funds to be awarded in 2027.

108

108

Pharmaceutical Commerce

AUGUST 19, 2024

The 86,000 square-foot Køge facility will be fully functional by 2027.

81

81

Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

75

75

Outsourcing Pharma

OCTOBER 24, 2023

Traditionally, the pharmaceutical landscape has been dominated by small molecules.

64

64

STAT

DECEMBER 7, 2023

One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.

FDA 129

FDA Compounding Pharmaceutical Companies Pharmaceutical Companies 129

The Guardian - Pharmaceutical Industry

SEPTEMBER 21, 2023

The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).

107

107

STAT

JULY 24, 2023

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging 98

Packaging Insurance Hospitals 98

STAT

JANUARY 17, 2023

The number of health care-related artificial intelligence models on the market has increased steadily over the past decade, with the health care AI market expected to grow from $7 billion today to $67 billion in 2027.

102

102

Fierce Pharma

SEPTEMBER 4, 2024

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team, a slimdown of its R&D program and decisive action on the future of | The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity covering (..)

55

55

Pharmaceutical Commerce

APRIL 5, 2023

Rise in value attributed to the ongoing decentralization of pharmacies.

52

52

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

77

77

STAT

OCTOBER 3, 2024

1, 2025, the Centers for Medicare and Medicaid Services will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.

101

101

European Pharmaceutical Review

NOVEMBER 2, 2022

Somewhat ambitious: Meet three percent of GDP by 2027, building on aspirations set out by the Confederation of British Industry (CBI), the European Commission (EC) and opposition political parties. The government would need to invest an extra £1 billion in R&D by 2027. Private investment would also need to rise by £0.8

Communication 98

Communication 98

European Pharmaceutical Review

AUGUST 27, 2024

Manufacturing of the biologic products in the expanded Sweden Biomanufacturing Center is planned to begin from Q4 of 2027, according to AstraZeneca. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden”, Alfredsson continued.

115

115

Fierce Pharma

DECEMBER 20, 2023

The sale is expected to go into effect in January 2027. . | In a deal worth around $116 million, Novartis is handing over a portfolio of “select ophthalmology brands” to Mumbai’s J.B. Chemicals & Pharmaceuticals. Until then, J.B. plans to distribute and market the medicines in India.

71

71

Pharmacy Times

JANUARY 17, 2025

As per the Inflation Reduction Act, the negotiations with the drug companies of the 15 drugs will occur in 2025, with the negotiated prices going into effect in 2027.

56

56

Pharmaceutical Technology

OCTOBER 6, 2023

Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.

59

59

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

109

109

Pharmaceutical Commerce

AUGUST 30, 2024

The 3PL plans to convert all its trucks to electric by 2027.

52

52

pharmaphorum

NOVEMBER 25, 2020

Jefferies expects that the company expects sales of $14 billion could be at risk by 2027 from patent expiries of Tasigna, Promacta, Jakavi, Gilenya and Entresto. In the short term, the analysts predict “flattish” Q4 sales, although they noted that the company may benefit from cost savings introduced during the COVID-19 pandemic.

Hospitals 119

Hospitals 119

STAT

NOVEMBER 20, 2023

Under the new agreement, the level of allowed growth in drug sales will increase from 2% in 2024 to 4% by 2027. The current plan, which has drawn the ire of pharma companies, requires drug companies to pay rebates back to the U.K. if spending on medicines increases by more than 2% a year. Continue to STAT+ to read the full story…

112

112

Pharmaceutical Commerce

JANUARY 25, 2023

Annual report finds continuing impact of COVID-19 on global markets

52

52

Pharmaceutical Technology

JANUARY 17, 2025

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

52

52

Fierce Healthcare

APRIL 4, 2024

Sacramento, California-based Sutter Health is getting called up to the big leagues next summer when the Oakland Athletics take up residence at a minor league park bearing its name. |

57

57